VIR GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Vir Biotechnology Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN ® dual-masked T-cell engagers iii across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website. Footnotes: i Huo, Xingyue et al. "Predicting Survival in Metastatic Castration-Resistant Prostate Cancer Patients: Development of a Prognostic Nomogram." Studies in health technology and informatics vol. 323 (2025): 164-168. doi:10.3233/SHTI250070 ii 50% premium to the 30 day volume weighted average share price as of February 19, 2026 iii Vir Biotechnology retains exclusive rights to the PRO-XTEN ® masking platform for oncology and infectious disease. PRO-XTEN ® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
Current Price
$8.79
-3.30%Profile
Valuation (TTM)
Market Cap$1.23B
P/E-2.77
EV—
P/B1.60
Shares Out139.52M
P/Sales18.72
Revenue$65.50M
EV/EBITDA—
Vir Biotechnology Inc (VIR) Quality Analysis
VIR Profitability
Profitability trend analysis coming soon
VIR Growth
Growth trend analysis coming soon
VIR Financial Health
Financial health indicators coming soon
VIR Quality & Fundamental Analysis
Vir Biotechnology Inc (VIR) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Vir Biotechnology Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Vir Biotechnology Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of -675.96% and a return on equity (ROE) of -57.85%. Return on assets (ROA) stands at -44.15%.
The debt-to-equity ratio is 0.12, with a current ratio of 5.54. Operating margin is -699.18%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Vir Biotechnology Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.